The rodent recovery spurs hope that humans could one day benefit from similar treatments.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
The demonstration in rodents could one day be combined with cochlear implants to treat more people than is currently possible.
IBM's Blue Gene supercomputer uncovers a novel drug interaction site.
A biotech company called Cerulean says its nanoparticle-delivered cancer drugs are better at attacking tumors.
The technique would retrain cells that typically don't respond to light.
Although Eli Lilly's anti-amyloid compound fails to slow decline in two large trials, patients with mild forms of the disease show some benefit
Researchers use DNA sequencing to identify the molecular basis of a patient's unique but beneficial response to an experimental cancer drug.
Surgeons have transplanted a second dose of neural cells into a patient's spinal cord in a pioneering trial.
The seasonal and unpredictable nature of the infection makes it difficult to test any potential treatment or vaccine.
Researchers at Harvard encode information in DNA at a density on par with any other experimental storage method.